Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic...
ThalassemiaSickle Cell Disease2 moreThis is an open-label, non-randomized, multi-center trial designed to provide expanded access of deferasirox to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with locally approved iron chelators.
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
Myelodysplastic SyndromeIron OverloadThe purpose of this trial is to examine the safety and efficacy of deferasirox in patients with Myelodysplastic Syndrome (MDS) and chronic iron overload from blood transfusions.
Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due...
Beta-ThalassemiaThe purpose of this study is to deterimine if the new orally active iron chelator, ICL670, is as effective and as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
Anemia (Iron-Loading)Beta-Thalassemia5 moreTo determine whether deferoxamine prevented the complications of transfusional iron overload.
Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major...
Thalassemia MajorThis study aims to investigate the use of amlodipine, a drug that blocks the uptake of calcium into cells, in the prevention and treatment of iron overload in patients with thalassemia major. Since iron uses the same calcium channels to enter the heart, pancreas and other organs, blocking these channels might help to prevent the accumulation of iron in these tissues. The study will follow 10 patients with thalassemia major: 5 will openly receive amlodipine and 5 will serve as controls, not receiving any additional drugs. Patients will be monitored through one year with an additional year of follow up after the group using amlodipine stops its use. Monitoring will occur through the measurement of blood ferritin as well as live and heart T2* by MRI.
Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
Beta-thalassemiaIron OverloadThe purpose of this trial is to evaluate changes in cardiac iron as measured by MRI T2* in beta-thalassemia patients with deferasirox treatment.
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron...
Iron OverloadAccelerated Phase Chronic Myelogenous Leukemia102 moreRATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload. PURPOSE: This pilot clinical trial studies safety and tolerability of deferasirox in hematopoietic stem cell transplant recipients who have iron overload. Effect of low dose deferasirox on labile plasma iron is also examined.
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant...
Breast CancerIron Overload6 moreRATIONALE: Deferasirox may be effective in treating iron overload caused by blood transfusions in patients who have undergone donor stem cell transplant. PURPOSE: This phase II trial is studying the side effects and how well deferasirox works in treating patients with iron overload after donor stem cell transplant.
Non-invasive Quantification of Liver Iron With MRI
Iron OverloadThis study is being conducted to build a library of prospectively collected clinical data from subjects with iron overload examined with commercially available MRI devices. This data library is intended for use in future engineering development and other research activities, including future regulatory submissions.
Treatment of Iron Overload Requiring Chelation Therapy
Transfusional Iron OverloadIron Overload5 moreThe purpose of this open-label study is to assess liver iron concentration using MRI imaging in subjects with beta-thalassemia when administered with either SPD602 or deferasirox for the treatment of chronic transfusional iron overload.